Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan reiterates conviction on overweight-rated Aberdeen

(Sharecast News) - JPMorgan Cazenove reiterated its conviction on Aberdeen on Thursday, having recently upgraded the shares to 'overweight' and placed them on 'positive catalyst watch' ahead of the first-half results on 30 July. "In particular, we would like to stress our expectation of a substantial improvement in flows within the Adviser vector, driven by a combination of stronger gross flows and especially lower redemptions," the bank said.

"Aberdeen has in the past mentioned that a large proportion of its outflows were adviser-led as opposed to customer-led (i.e. advisers so dissatisfied that they decided to move their clients' AUM somewhere else).

"We believe that the bar to stop adviser-led outflows is low, as we see this as a solution of last resort for advisers who would rather avoid the complex and time-consuming process of migrating AUM to another platform."

JPM said the substantial price reduction implemented by Aberdeen in the first quarter, paired with an improved customer service, should therefore result in a material reduction in outflows.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.